RS
AKBA icon

R Squared’s Akebia Therapeutics AKBA Stock Holding History

R Squared’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8K Buy
+25,295
New +$30.1K 0.02% 473

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

R Squared's AKBA Position: Q2 2026 in Review

R Squared opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 25,295 shares worth $28.8K. The stake represents 0.02% of the portfolio and ranks #473 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • R Squared held 25,295 shares of Akebia Therapeutics worth $28.8K as of Q2 2026.
  • Akebia Therapeutics was a new R Squared position in Q2 2026.
  • Akebia Therapeutics made up 0.02% of R Squared's portfolio in Q2 2026, its #473 holding.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.